Evidence map›Paper›PMID 27726312›Full record

Observational studyCancer medicine2016

A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.

Graeme P Young, Susanne K Pedersen, Scott Mansfield, David H Murray, Rohan T Baker, Philippa Rabbitt, Susan Byrne, Libby Bambacas, Paul Hollington, Erin L Symonds

Open access · goldAbstract readComparative StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. A review on trends in development and translation of omics signatures in cancer.Computational and structural biotechnology journal · 2024
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Graeme P YoungFlinders Centre for Innovation in Cancer, Flinders University of South Australia, Bedford Park, South Australia, Australia. graeme.young@flinders.edu.au.
Susanne K PedersenClinical Genomics Pty Ltd, North Ryde, New South Wales, Australia.
Scott MansfieldColorectal Surgery, Division of Surgery & Perioperative Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia.
David H MurrayClinical Genomics Pty Ltd, North Ryde, New South Wales, Australia.
Rohan T BakerClinical Genomics Pty Ltd, North Ryde, New South Wales, Australia.
Philippa RabbittColorectal Surgery, Division of Surgery & Perioperative Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia.
Susan ByrneFlinders Centre for Innovation in Cancer, Flinders University of South Australia, Bedford Park, South Australia, Australia.
Libby BambacasFlinders Centre for Innovation in Cancer, Flinders University of South Australia, Bedford Park, South Australia, Australia.
Paul HollingtonColorectal Surgery, Division of Surgery & Perioperative Medicine, Flinders Medical Centre, Bedford Park, South Australia, Australia.
Erin L SymondsFlinders Centre for Innovation in Cancer, Flinders University of South Australia, Bedford Park, South Australia, Australia.
Flinders Medical Centre · AUID Genomics (United States) · USFlinders University · AURepatriation General Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recurrence will develop in 30-50% of colorectal cancer (CRC) cases despite apparent clearance following treatment. Carcinoembryonic antigen (CEA) is the only guideline-recommended blood test for monitoring cases for recurrence, but its sensitivity and specificity are suboptimal. This observational study compared a novel 2-gene (methylated BCAT1 and IKZF1 DNA) blood test with CEA for detection of recurrent CRC. We conducted a paired comparison of the BCAT1/IKZF1 test with CEA (cut-off 5 ng/mL) in blood from patients in remission after treatment for primary CRC and undergoing surveillance. Blood collected in the 12 months prior to or 3 months after complete investigational assessment of recurrence status were assayed and the results compared by McNemar's test. Of 397 patients enrolled, 220 underwent satisfactory assessment for recurrence and 122 had blood testing performed within the prescribed period. In 28 cases with recurrent CRC, CEA was positive in 9 (32%; 95% CI 16-52%) compared to 19 (68%; 95% CI 48-84%) positive for methylated BCAT1/IKZF1 (P = 0.002). All samples that were CEA positive were also BCAT1/IKZF1 positive. In 94 patients without clinically detectable recurrence, CEA was positive in 6 (6%, 95% CI 2-13%) and BCAT1/IKZF1 in 12 (13%, 95% CI 7-21%), P = 0.210. The odds ratio of a positive CEA test for recurrence was 6.9 (95% CI 2-22) compared to 14.4 (5-39) for BCAT1/IKZF1. The BCAT1/IKZF1 test was more sensitive for recurrence than CEA and the odds of recurrence given a positive test was twice that of CEA. The BCAT1/IKZF1 test should be further considered for monitoring cases for recurrence.

Indexed as

DNA MethylationAgedCarcinoembryonic AntigenColorectal NeoplasmsCross-Sectional StudiesFemaleHumansIkaros Transcription FactorMaleMiddle AgedNeoplasm Recurrence, LocalSensitivity and SpecificityTransaminasesWatchful WaitingBCAT1 protein, humanCarcinoembryonic AntigenIkaros Transcription FactorIKZF1 protein, humanTransaminasesBCAT1carcinoembryonic antigenColorectal cancer recurrenceIKZF1monitoring, circulating tumor-derived DNA

Identifiers

PMID27726312
PMCPMC5083729
OpenAlexW2531463553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.